Myrexis, Inc.

ACTIVE

600 5TH Ave FL 2, New York City, New York, United Stateswww.myrexis.comPublic11–50 employeesEstablished: 1999-01-01

Clinical Trials

0 active

Approvals

Total approvals

Agencies

Regulatory bodies

Founded

1999

Overview

Trial Phase Distribution

Phase

Trials

Phase 2

46.7%

Phase 1

33.3%

Phase 3

20.0%

Trial Status Distribution

Completed

66.7%

Terminated

20.0%

Unknown

13.3%

Clinical Trials

Trials sponsored by this organization (15)

Verubulin, Radiation Therapy, and Temozolomide to Treat Patients With Newly Diagnosed Glioblastoma Multiforme

Phase 2

Completed

interventional

Dec 20105 participants

A Study to Assess the Long-term Efficacy (24 Weeks) of MPC-4326 in Combination With a 2-3 Drug OBR Relative to the Efficacy of a 3-4 Drug ARV Regimen in Treatment Experienced HIV-1 Infected Subjects Who Are Failing Current Antiretroviral Therapy

Phase 2

Terminated

interventional

Nov 20092 participants

Safety Study of MPC-3100 in Cancer Patients Who Have Failed Other Treatments

Phase 1

Completed

interventional

Jun 200926 participants

Phase 2 Study MPC-6827 for Recurrent Glioblastoma Multiforme

Phase 2

Completed

interventional

Apr 200956 participants

A Phase 2 Study to Assess the Pharmacokinetics of Bevirimat 100 mg Tablets Given to HIV-1 Positive Patient for 15 Days

Phase 2

Completed

interventional

Nov 200835 participants

Safety and Efficacy Study of MPC-4326 for Treatment of Patients With HIV-1 Infection.

Phase 2

Completed

interventional

May 200832 participants

Phase 1 Study of MPC-6827 and Carboplatin in Recurrent/Relapsed Glioblastoma Multiforme

Phase 1

Unknown

interventional

Mar 200830 participants

Phase 1 Study of MPC-6827 and Temozolomide in Metastatic Melanoma

Phase 1

Completed

interventional

Mar 200822 participants

Page 1 of 2

Approvals

No approval data available

News

No news articles found

Back to Organizations